@article{b96b7e4751d54c56ba3a5e7997a6f004,
title = "Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways",
abstract = "Radiotherapy is one of the most widely used treatments for cancer; however, the development of tumor radioresistance is an ongoing problem. Agents that target tumor angiogenesis are being used in combination with radiotherapy to improve the therapeutic index without a clear understanding of how these agents may affect radiosensitization. This article discusses recently published studies that may shed some light on the underlying signaling mechanisms that are involved in the interactions of antiangiogenic agents with ionizing radiation.",
author = "Phyllis Wachsberger and Randy Burd and Dicker, {Adam P.}",
note = "Funding Information: This work was supported in part by P30CA56036-03 (NCI), a Bridge Grant to Dr. Dicker from the Office of the Dean, Thomas Jefferson University, and seed grants from the Radiation Therapy Oncology Group (RTOG) to Drs. Wachsberger and Dicker as well as a grant to the Radiation Therapy Oncology Group (Commonwealth of Pennsylvania, Tobacco Settlement Act) to Drs. Burd and Dicker. Dr. Wachsberger has unrestricted grants from AstraZeneca, Regeneron, and Abbot pharmaceuticals. Dr. Dicker has unrestricted grants from Pharmacia, Regeneron, and AstraZeneca. Dr. Burd has unrestricted grants from Aventis, Regeneron, and AstraZeneca. ",
year = "2004",
month = oct,
doi = "10.1016/j.hoc.2004.06.007",
language = "English (US)",
volume = "18",
pages = "1039--1057",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders",
number = "5",
}